We are live on ! Find out more
JB

Julian Baker Baker Bros. Advisors

AUM $20B
1-Year Est. Return 154.41%
 

Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.

This Fund
S&P 500
This Quarter Est. Return
+4.24%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$7.94B
AUM Growth
-$224M
Cap. Flow
-$1.92B
Cap. Flow %
-24.14%
Top 10 Hldgs %
74.98%
Holding
115
New
11
Increased
21
Reduced
12
Closed
7

Top Buys

Rank Stock Value
1
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$30.4M
2
ANAC
ANACOR PHARMACEUTICALS INC COM
ANAC
+$19.4M
3
AVNR
AVANIR PHARMACEUTICALS, INC CL A
AVNR
+$16.5M
4
MNK
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
+$15.8M
5
XNPT
XENOPORT, INC.
XNPT
+$13.6M

Top Sells

Rank Stock Value
1
ITMN
INTERMUNE INC
ITMN
+$209M
2
QCOR
QUESTCOR PHARMA INC
QCOR
+$46.2M
3
CLVS
Clovis Oncology, Inc.
CLVS
+$32.8M
4
SLXP
SALIX PHARMACEUTICALS LTD DEL
SLXP
+$18.1M
5
AEGR
Aegerion Pharmaceuticals
AEGR
+$13.3M

Sector Composition

Rank Sector Weight
1 Healthcare 44.26%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TGTX icon
26
TG Therapeutics
TGTX
$8.31B
$21.9M 0.28%
2,050,313
-110,652
-5% -$1.03M
HRTX icon
27
Heron Therapeutics
HRTX
$60.4M
$21.7M 0.27%
2,607,784
– –
MNK
28
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
$18.2M 0.23%
+201,856
New +$15.8M
ARWR icon
29
Arrowhead Research
ARWR
$12.3B
$18.2M 0.23%
1,230,802
-200,000
-14% -$2.73M
AMBI
30
DELISTED
Ambit Biosciences Corp
AMBI
$16.8M 0.21%
1,093,332
+345,378
+46% +$2.37M
INSM icon
31
Insmed
INSM
$27.5B
$14.5M 0.18%
1,107,850
+803,800
+264% +$12.1M
AGIO icon
32
Agios Pharmaceuticals
AGIO
$1.98B
$10.4M 0.13%
169,893
-30,000
-15% -$1.29M
OMER icon
33
Omeros
OMER
$1.39B
$10.3M 0.13%
808,775
+54,971
+7% +$770K
ABUS icon
34
Arbutus Biopharma
ABUS
$1.03B
$10.2M 0.13%
484,156
– –
KYTH
35
DELISTED
KYTHERA BIOPHARMACEUTICALS, INC COM
KYTH
$10.2M 0.13%
311,255
– –
SGMO
36
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$9.33M 0.12%
864,856
+342,092
+65% +$4.47M
NBIX icon
37
Neurocrine Biosciences
NBIX
$15.5B
$8.69M 0.11%
554,590
– –
RARE icon
38
Ultragenyx Pharmaceutical
RARE
$2.55B
$8.49M 0.11%
150,000
+50,000
+50% +$2.52M
NGNE icon
39
Neurogene
NGNE
$773M
$8.07M 0.1%
60,593
– –
MTEM
40
DELISTED
Molecular Templates, Inc.
MTEM
$7.79M 0.1%
13,080
+2,011
+18% +$1.39M
QLTI
41
DELISTED
QLT Inc
QLTI
$6.94M 0.09%
1,535,863
– –
PRQR icon
42
ProQR Therapeutics
PRQR
$330M
$6.88M 0.09%
+400,000
New +$6.41M
WINT
43
DELISTED
Windtree Therapeutics Inc
WINT
$6.72M 0.08%
260,866
– –
MGNX icon
44
MacroGenics
MGNX
$261M
$6.52M 0.08%
311,891
– –
OSIR
45
DELISTED
Osiris Therapeutics, Inc. Common Stock
OSIR
$6.43M 0.08%
510,606
– –
AERI
46
DELISTED
Aerie Pharmaceuticals
AERI
$6.19M 0.08%
299,356
– –
EPZM
47
DELISTED
Epizyme, Inc
EPZM
$5.8M 0.07%
214,012
– –
CNCE
48
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$5.69M 0.07%
451,496
+52,696
+13% +$511K
FOMX
49
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$5.57M 0.07%
+1,021,600
New +$5.87M
BLUE
50
DELISTED
bluebird bio
BLUE
$5.38M 0.07%
11,580
-3,726
-24% -$1.72M
1
2
3 4 5

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Julian Baker's Q3 2014 Portfolio in Review

As of Q3 2014, Julian Baker held 115 positions worth $7.94B, down 2.7% from $8.16B the previous quarter. Its ten largest holdings account for 75% of the portfolio.

Julian Baker withdrew a net $1.92B in Q3 2014, closing 7 positions and reducing 12 holdings. Its most notable exit was INTERMUNE INC, an estimated $209M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 44% of assets, down from 45% a quarter earlier.

Against the trend, Julian Baker opened a new position in MALLINCKRODT PUBLIC LIMITED COMPANY worth $18.2M.

  • Julian Baker's largest Q3 2014 buy was MALLINCKRODT PUBLIC LIMITED COMPANY: 201,856 shares worth $18.2M.
  • Julian Baker added most to BioMarin Pharmaceuticals in Q3 2014, an estimated $30.4M increase.
  • Julian Baker's biggest Q3 2014 reduction was SALIX PHARMACEUTICALS LTD DEL, cutting an estimated $18.1M.
  • Julian Baker fully exited INTERMUNE INC in Q3 2014, selling an estimated $209M.
  • Julian Baker's ten largest holdings make up 75% of its $7.94B portfolio in Q3 2014.
  • Julian Baker opened 11 new positions and closed 7 in Q3 2014.
  • Julian Baker's portfolio value fell 2.7% quarter-over-quarter to $7.94B.

Based on Baker Bros. Advisors's 13F filing for Q3 2014, filed 14 Nov 2014.